Tectonic Therapeutic soars on prelim pulmonary hypertension drug data

Tectonic Therapeutic

30/01/2025 19:07

** Shares of drug developer Tectonic Therapeutic  TECX.O 
rise ~104% to $52.50, set for record single-day pct gain
    ** TECX says its experimental drug, TX45, showed improved
blood flow and reduced pressure in lungs and heart in an
early-stage trial
    ** TECX is testing TX45 to treat patients with group 2
pulmonary hypertension, a condition where high lung blood
pressure is caused by left-sided heart disease, leading to
symptoms such as shortness of breath, fatigue, and swelling in
the legs and feet
    ** TX45 was well-tolerated and had no serious side effects
in patients - TECX
    ** The condition currently has no approved treatments
    ** TECX more than doubled in 2024

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))